NCT03168022View on ClinicalTrials.gov

Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 16, 2015

Primary Completion Date

January 26, 2016

Study Completion Date

January 26, 2016

Conditions
Healthy Adults
Interventions
DRUG

Treatment A

1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.

DRUG

Treatment B

1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.

Trial Locations (1)

GIP )A2

InVentiv Health Clinique Inc., Québec

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT03168022 - Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. | Biotech Hunter | Biotech Hunter